




RealRate

PHARMACEUTICAL 2020

Orgenesis Inc.
Rank 206 of 358





RealRate

PHARMACEUTICAL 2020

Orgenesis Inc.
Rank 206 of 358



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Orgenesis Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 16% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	25,979
Cost of Goods Sold	18,232
Intangible Assets	29,147
Liabilities, Current	31,579
Liabilities, Non-Current	23,883
Other Assets	12,915
Other Compr. Net Income	1,464
Other Expenses	2,624
Other Liabilities	0
Other Net Income	-874
Other Revenues	33,484
Property and Equipment	24,454
Research and Development	12,458
Selling, General and Administrative Expense	25,337

Output Variable	Value in 1000 USD
Assets	92,495
Liabilities	55,462
Expenses	58,651
Revenues	33,484
Stockholders Equity	37,033
Net Income	-26,041
Comprehensive Net Income	-25,309
Economic Capital Ratio	52%